Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids

Geurts MH, de Poel E, Pleguezuelos-Manzano C, Oka R, Carrillo L, Andersson-Rolf A, Boretto M, Brunsveld JE, van Boxtel R, Beekman JM, Clevers H

View at source ↗PDF ↗Article121 citations

Abstract

Prime editing is a recently reported genome editing tool using a nickase-cas9 fused to a reverse transcriptase that directly synthesizes the desired edit at the target site. Here, we explore the use of prime editing in human organoids. Common TP53 mutations can be correctly modeled in human adult stem cell-derived colonic organoids with efficiencies up to 25% and up to 97% in hepatocyte organoids. Next, we functionally repaired the cystic fibrosis CFTR-F508del mutation and compared prime editing to CRISPR/Cas9-mediated homology-directed repair and adenine base editing on the CFTR-R785* mutation. Whole-genome sequencing of prime editing-repaired organoids revealed no detectable off-target effects. Despite encountering varying editing efficiencies and undesired mutations at the target site, these results underline the broad applicability of prime editing for modeling oncogenic mutations and showcase the potential clinical application of this technique, pending further optimization.

Abstract of "Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids" by Geurts MH, de Poel E, Pleguezuelos-Manzano C et al., https://doi.org/10.26508/lsa.202000940, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.

Record

Archive ID
doi:10.26508/lsa.202000940
Published
Aug 9, 2021
Venue
Life science alliance
DOI
10.26508/lsa.202000940
PubMed
34373320
PMC
PMC8356249
License
CC-BY
Provenance
europepmc

Topics